ArticleFrontiers in nutrition2025
Hypertriglyceridemia as an independent predictor of adverse prognosis in female patients with acute myocardial infarction: a comprehensive retrospective cohort study.
Article in Frontiers in nutrition, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Acute myocardial infarction (AMI) has notable sex-specific differences in clinical outcomes. While low-density lipoprotein cholesterol (LDL-C) is a longstanding core for atherosclerotic cardiovascular disease (ASCVD) risk assessment, the prognostic value of hypertriglyceridemia (HTG) in AMI patients-especially its sex-specific impact-remains unclear. This gap is critical as HTG is more common in women but understudied in post-AMI populations. Methods: A retrospective cohort included 850 consecutive AMI patients (412 females, 438 males) admitted to the Seventh Affiliated Hospital of Sun Yat-sen University (Jan 2019-Dec 2024), stratified by HTG (triglycerides ≥2.2 mmol/L). Median follow-up was 2.6 years, with outcomes: all-cause death, heart failure, major adverse cardiovascular events (MACE). Confounding was controlled via multivariate Cox regression, E-value calculation, and 1:1 propensity score matching. HTG's predictive value was assessed via receiver operating characteristic (ROC) curves; Results: HTG prevalence was 35.1% overall (females 54.4% vs. males 31.1%). HTG patients had higher all-cause death (18.8% vs. 4.7%), heart failure (20.8% vs. 5.3%), and MACE (21.8% vs. 5.4%). Female HTG patients had the highest event rates (all-cause death 28.4%, heart failure 30.2%, MACE 31.5%), while males with HTG only had higher MACE (11.0% vs. 5.3%). HTG independently predicted all outcomes in females (death HR = 3.89, heart failure HR = 4.21, MACE HR = 4.35) but only weakly associated with male MACE (HR = 2.05). E-value (4.2 for female death) and matching (284 patients, female death HR = 3.62) validated robustness. Adding HTG improved death prediction (ROC AUC 0.78 vs. 0.73) with net reclassification improvement 0.23. Conclusion: HTG is a strong independent predictor of adverse AMI outcomes, with a far stronger effect in females. Routine triglyceride screening and targeted therapies (e.g., fibrates, icosapent ethyl) are needed for female AMI patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.